hig.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard-cite-them-right
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • sv-SE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • de-DE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Differences in trial knowledge and motives for participation among cancer patients in phase 3 clinical trials
Uppsala universitet, Centrum för forsknings- och bioetik.
Uppsala universitet, Centrum för forsknings- och bioetik.
Uppsala universitet; University of Bergen, Bergen, Norway.
Uppsala universitet, Vårdvetenskap.
Visa övriga samt affilieringar
2015 (Engelska)Ingår i: European Journal of Cancer Care, ISSN 0961-5423, E-ISSN 1365-2354, Vol. 25, nr 3, s. 516-523Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

While participants in clinical oncology trials are essential for the advancement of cancer therapies, factors decisive for patient participation have been described but need further investigation, particularly in the case of phase 3 studies. The aim of this study was to investigate differences in trial knowledge and motives for participation in phase 3 clinical cancer trials in relation to gender, age, education levels and former trial experience. The results of a questionnaire returned from 88 of 96 patients (92%) were analysed using the Mann-Whitney U-test. There were small, barely relevant differences in trial knowledge among patients when stratified by gender, age or education. Participants with former trial experience were less aware about the right to withdraw. Male participants and those aged ≥65 years were significantly more motivated by a feeling of duty, or by the opinions of close ones. Men seem more motivated than women by external factors. With the awareness that elderly and single male participants might be a vulnerable group and participants with former trial experience are less likely to be sufficiently informed, the information consent process should focus more on these patients. We conclude that the informed consent process seems to work well, with good results within most subgroups.

Ort, förlag, år, upplaga, sidor
2015. Vol. 25, nr 3, s. 516-523
Nyckelord [en]
adults, cancer, clinical trials, patient education, patient information, phase 3 trials
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:hig:diva-20510DOI: 10.1111/ecc.12319ISI: 000375066900018PubMedID: 25904313Scopus ID: 2-s2.0-84928316987OAI: oai:DiVA.org:hig-20510DiVA, id: diva2:865754
Tillgänglig från: 2015-05-08 Skapad: 2015-10-29 Senast uppdaterad: 2018-03-13Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMedScopus

Personposter BETA

Silén, Marit

Sök vidare i DiVA

Av författaren/redaktören
Silén, Marit
I samma tidskrift
European Journal of Cancer Care
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 439 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard-cite-them-right
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • sv-SE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • de-DE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf